BackBioventus Overview
Bioventus Inc - Ordinary Shares - Class A

Bioventus Target Price

Where could BVS trade next? Consensus target price: $18.

Get informed when a big investor buys or sells

+ Follow

Share Price

$14.07

Average Target Price

$17.5024.4% upside

4 analysts in the last 4 months

High: $19 | Low: $15

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-17Canaccord Genuity$1935% upsideOpen
2026-08-06Craig-Hallum$1827.9% upsideOpen
2026-08-06Barrington$1827.9% upsideOpen
2026-06-16Canaccord GenuityCaitlin Cronin$156.6% upsideOpen
2026-02-09Barrington$137.6% downsideOpen
2025-05-07Craig-HallumChase Knickerbocker$156.6% upsideOpen
2024-10-01Canaccord GenuityCaitlin Cronin$1214.7% downsideOpen
2024-08-07Craig-HallumChase Knickerbocker$1214.7% downsideOpen
2024-05-07Canaccord GenuityWilliam Plovanic$843.1% downsideOpen
2024-03-13Craig-HallumAlex Nowak$936% downsideOpen
2022-11-30Goldman Sachs$2.582.2% downsideOpen

Bioventus (BVS) FAQ

The latest target price for BVS is $18. Investors often review this figure alongside Bioventus's historical trend and sector peers before judging valuation or financial health.

Bioventus trades near $14.07 while the consensus target sits at $18 (24.4% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting BVS's target price ($18), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Bioventus's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.